Giuseppe Quero

Closest collaborators

The 25 strongest of 53 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Sergio Alfieri · 13 shared papers, 2019–2026 · strength 2.14
   • Paper Surgical treatment of synchronous liver-only oligometastatic pancreatic adenocarcinoma: a systematic review and meta-an… DOI 10.1097/js9.0000000000002338↗
   • Paper Designing a national network of pancreas units: the Italian model for high-quality pancreatic cancer care. DOI 10.1007/s13304-026-02598-7↗
   • Paper Understanding the Conundrum of Pancreatic Cancer in the Omics Sciences Era. DOI 10.3390/ijms25147623↗
2. Giampaolo Tortora · 7 shared papers, 2021–2026 · strength 1.06
   • Paper Designing a national network of pancreas units: the Italian model for high-quality pancreatic cancer care. DOI 10.1007/s13304-026-02598-7↗
   • Paper Nutritional Interventions during Chemotherapy for Pancreatic Cancer: A Systematic Review of Prospective Studies. DOI 10.3390/nu15030727↗
   • Paper An alternative splicing signature defines the basal-like phenotype and predicts worse clinical outcome in pancreatic ca… DOI 10.1016/j.xcrm.2024.101411↗
3. Claudio Fiorillo · 4 shared papers, 2019–2025 · strength 0.70
   • Paper Surgical treatment of synchronous liver-only oligometastatic pancreatic adenocarcinoma: a systematic review and meta-an… DOI 10.1097/js9.0000000000002338↗
   • Paper Immunohistochemical Evaluation of the Expression of Specific Membrane Antigens in Patients with Pancreatic Ductal Adeno… DOI 10.3390/cancers15184586↗
   • Paper Resection margin status in pancreatic cancer surgery: is it really less important than the N status? DOI 10.1002/bjs.11356↗
4. Carmine Carbone · 4 shared papers, 2021–2024 · strength 0.55
   • Paper An alternative splicing signature defines the basal-like phenotype and predicts worse clinical outcome in pancreatic ca… DOI 10.1016/j.xcrm.2024.101411↗
   • Paper Spatial transcriptomics identified mucin-specific O-glycosylation as a key pathway in pancreatic cancer development and… DOI 10.21203/rs.3.rs-2095432/v1↗
   • Paper Talniflumate abrogates mucin immune suppressive barrier improving efficacy of gemcitabine and nab-paclitaxel treatment … DOI 10.1186/s12967-023-04733-z↗
5. Lisa Salvatore · 3 shared papers, 2022–2023 · strength 0.44
   • Paper Nutritional Interventions during Chemotherapy for Pancreatic Cancer: A Systematic Review of Prospective Studies. DOI 10.3390/nu15030727↗
   • Paper The role of the multidisciplinary tumor board (MDTB) in the assessment of pancreatic cancer diagnosis and resectability… DOI 10.3389/fsurg.2023.1119557↗
   • Paper Role of Chemoradiation in the Adjuvant Treatment of Radically Resected Pancreatic Cancer Patients: A Mono-Institutional… DOI 10.1159/000525945↗
6. Valentina Panzeri · 2 shared papers, 2024–2026 · strength 0.41
   • Paper U2 snRNP inhibition hampers pancreatic cancer cell viability by disrupting DNA repair proficiency and mitotic checkpoin… DOI 10.1186/s13046-026-03795-3↗
   • Paper An alternative splicing signature defines the basal-like phenotype and predicts worse clinical outcome in pancreatic ca… DOI 10.1016/j.xcrm.2024.101411↗
7. Claudio Sette · 2 shared papers, 2024–2026 · strength 0.41
   • Paper U2 snRNP inhibition hampers pancreatic cancer cell viability by disrupting DNA repair proficiency and mitotic checkpoin… DOI 10.1186/s13046-026-03795-3↗
   • Paper An alternative splicing signature defines the basal-like phenotype and predicts worse clinical outcome in pancreatic ca… DOI 10.1016/j.xcrm.2024.101411↗
8. Veronica Ruta · 2 shared papers, 2024–2026 · strength 0.41
   • Paper U2 snRNP inhibition hampers pancreatic cancer cell viability by disrupting DNA repair proficiency and mitotic checkpoin… DOI 10.1186/s13046-026-03795-3↗
   • Paper An alternative splicing signature defines the basal-like phenotype and predicts worse clinical outcome in pancreatic ca… DOI 10.1016/j.xcrm.2024.101411↗
9. Alberto Larghi · 3 shared papers, 2021–2023 · strength 0.39
   • Paper Spatial transcriptomics identified mucin-specific O-glycosylation as a key pathway in pancreatic cancer development and… DOI 10.21203/rs.3.rs-2095432/v1↗
   • Paper Talniflumate abrogates mucin immune suppressive barrier improving efficacy of gemcitabine and nab-paclitaxel treatment … DOI 10.1186/s12967-023-04733-z↗
   • Paper Pancreatic Cancer Patient-Derived Organoid Platforms: A Clinical Tool to Study Cell- and Non-Cell-Autonomous Mechanisms… DOI 10.3389/fmed.2021.793144↗
10. Antonio Agostini · 3 shared papers, 2021–2023 · strength 0.39
    • Paper Spatial transcriptomics identified mucin-specific O-glycosylation as a key pathway in pancreatic cancer development and… DOI 10.21203/rs.3.rs-2095432/v1↗
    • Paper Talniflumate abrogates mucin immune suppressive barrier improving efficacy of gemcitabine and nab-paclitaxel treatment … DOI 10.1186/s12967-023-04733-z↗
    • Paper Pancreatic Cancer Patient-Derived Organoid Platforms: A Clinical Tool to Study Cell- and Non-Cell-Autonomous Mechanisms… DOI 10.3389/fmed.2021.793144↗
11. Geny Piro · 3 shared papers, 2021–2023 · strength 0.39
    • Paper Spatial transcriptomics identified mucin-specific O-glycosylation as a key pathway in pancreatic cancer development and… DOI 10.21203/rs.3.rs-2095432/v1↗
    • Paper Talniflumate abrogates mucin immune suppressive barrier improving efficacy of gemcitabine and nab-paclitaxel treatment … DOI 10.1186/s12967-023-04733-z↗
    • Paper Pancreatic Cancer Patient-Derived Organoid Platforms: A Clinical Tool to Study Cell- and Non-Cell-Autonomous Mechanisms… DOI 10.3389/fmed.2021.793144↗
12. Federica Vitale · 2 shared papers, 2023–2024 · strength 0.37
    • Paper Understanding the Conundrum of Pancreatic Cancer in the Omics Sciences Era. DOI 10.3390/ijms25147623↗
    • Paper Immunohistochemical Evaluation of the Expression of Specific Membrane Antigens in Patients with Pancreatic Ductal Adeno… DOI 10.3390/cancers15184586↗
13. Lorenzo Zileri Dal Verme · 2 shared papers, 2023–2024 · strength 0.37
    • Paper Understanding the Conundrum of Pancreatic Cancer in the Omics Sciences Era. DOI 10.3390/ijms25147623↗
    • Paper Immunohistochemical Evaluation of the Expression of Specific Membrane Antigens in Patients with Pancreatic Ductal Adeno… DOI 10.3390/cancers15184586↗
14. Alberto Nicoletti · 2 shared papers, 2023–2024 · strength 0.37
    • Paper Understanding the Conundrum of Pancreatic Cancer in the Omics Sciences Era. DOI 10.3390/ijms25147623↗
    • Paper Immunohistochemical Evaluation of the Expression of Specific Membrane Antigens in Patients with Pancreatic Ductal Adeno… DOI 10.3390/cancers15184586↗
15. Valerio Papa · 2 shared papers, 2023 · strength 0.33
    • Paper The Role of Microbiota in Pancreatic Cancer. DOI 10.3390/cancers15123143↗
    • Paper The role of the multidisciplinary tumor board (MDTB) in the assessment of pancreatic cancer diagnosis and resectability… DOI 10.3389/fsurg.2023.1119557↗
16. Paola Saccomandi · 2 shared papers, 2018–2023 · strength 0.31
    • Paper Optimization of laser dosimetry based on patient-specific anatomical models for the ablation of pancreatic ductal adeno… DOI 10.1038/s41598-023-37859-7↗
    • Paper Thermal ablation of pancreatic cancer: A systematic literature review of clinical practice and pre-clinical studies. DOI 10.1080/02656736.2018.1506165↗
17. Alessia Caggiano · 2 shared papers, 2022–2023 · strength 0.27
    • Paper Spatial transcriptomics identified mucin-specific O-glycosylation as a key pathway in pancreatic cancer development and… DOI 10.21203/rs.3.rs-2095432/v1↗
    • Paper Talniflumate abrogates mucin immune suppressive barrier improving efficacy of gemcitabine and nab-paclitaxel treatment … DOI 10.1186/s12967-023-04733-z↗
18. Vincenzo Corbo · 2 shared papers, 2022–2023 · strength 0.27
    • Paper Spatial transcriptomics identified mucin-specific O-glycosylation as a key pathway in pancreatic cancer development and… DOI 10.21203/rs.3.rs-2095432/v1↗
    • Paper Talniflumate abrogates mucin immune suppressive barrier improving efficacy of gemcitabine and nab-paclitaxel treatment … DOI 10.1186/s12967-023-04733-z↗
19. Juan Carlos López-Gil · 1 shared paper, 2026 · strength 0.25
    • Paper U2 snRNP inhibition hampers pancreatic cancer cell viability by disrupting DNA repair proficiency and mitotic checkpoin… DOI 10.1186/s13046-026-03795-3↗
20. Ana Galván-del-Rey · 1 shared paper, 2026 · strength 0.25
    • Paper U2 snRNP inhibition hampers pancreatic cancer cell viability by disrupting DNA repair proficiency and mitotic checkpoin… DOI 10.1186/s13046-026-03795-3↗
21. Carmen E. Guerra · 1 shared paper, 2026 · strength 0.25
    • Paper U2 snRNP inhibition hampers pancreatic cancer cell viability by disrupting DNA repair proficiency and mitotic checkpoin… DOI 10.1186/s13046-026-03795-3↗
22. Teresa Mezza · 1 shared paper, 2025 · strength 0.22
    • Paper Surgical treatment of synchronous liver-only oligometastatic pancreatic adenocarcinoma: a systematic review and meta-an… DOI 10.1097/js9.0000000000002338↗
23. Ilaria Tarantino · 1 shared paper, 2026 · strength 0.22
    • Paper Designing a national network of pancreas units: the Italian model for high-quality pancreatic cancer care. DOI 10.1007/s13304-026-02598-7↗
24. Carlo Fabbri · 1 shared paper, 2026 · strength 0.22
    • Paper Designing a national network of pancreas units: the Italian model for high-quality pancreatic cancer care. DOI 10.1007/s13304-026-02598-7↗
25. Evaristo Maiello · 1 shared paper, 2026 · strength 0.22
    • Paper Designing a national network of pancreas units: the Italian model for high-quality pancreatic cancer care. DOI 10.1007/s13304-026-02598-7↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.